PDF(Pubmed)
Abstract：
UNASSIGNED: The role of stereotactic ablative radiation therapy (SABR) as local treatment option after chemotherapy for locally advanced pancreatic cancer (LAPC) is evolving. However adequate patient selection criteria for SABR in patients with LAPC are lacking.
UNASSIGNED: A prospective institutional database collected data of patients with LAPC treated with chemotherapy, mainly FOLFIRINOX, followed by SABR, which was delivered using magnetic resonance guided radiotherapy, 40 Gy in 5 fractions within two weeks. Primary endpoint was overall survival (OS). Cox regression analyses were performed to identify predictors for OS.
UNASSIGNED: Overall, 74 patients were included, median age 66 years, 45.9% had a KPS score of ≥90. Median OS was 19.6 months from diagnosis and 12.1 months from start of SABR. Local control was 90% at one year. Multivariable Cox regression analyses identified KPS ≥90, age <70, and absence of pain prior to SABR as independent favorable predictors for OS. The rate of grade ≥3 fatigue and late gastro-intestinal toxicity was 2.7%.
UNASSIGNED: SABR is a well-tolerated treatment in patients with unresectable LAPC following chemotherapy, with better outcomes when applied in patients with higher performance score, age <70 years and absence of pain. Future randomized trials will have to confirm these findings.
UNASSIGNED: A prospective institutional database collected data of patients with LAPC treated with chemotherapy, mainly FOLFIRINOX, followed by SABR, which was delivered using magnetic resonance guided radiotherapy, 40 Gy in 5 fractions within two weeks. Primary endpoint was overall survival (OS). Cox regression analyses were performed to identify predictors for OS.
UNASSIGNED: Overall, 74 patients were included, median age 66 years, 45.9% had a KPS score of ≥90. Median OS was 19.6 months from diagnosis and 12.1 months from start of SABR. Local control was 90% at one year. Multivariable Cox regression analyses identified KPS ≥90, age <70, and absence of pain prior to SABR as independent favorable predictors for OS. The rate of grade ≥3 fatigue and late gastro-intestinal toxicity was 2.7%.
UNASSIGNED: SABR is a well-tolerated treatment in patients with unresectable LAPC following chemotherapy, with better outcomes when applied in patients with higher performance score, age <70 years and absence of pain. Future randomized trials will have to confirm these findings.
摘要：
■立体定向消融放射治疗（SABR）作为局部晚期胰腺癌（LAPC）化疗后的局部治疗选择的作用正在演变。然而，缺乏LAPC患者SABR的适当患者选择标准。
■前瞻性机构数据库收集了接受化疗的LAPC患者的数据，主要是FIRINOX，其次是SABR,使用磁共振引导放射治疗，40Gy在两周内的5个分数。主要终点是总生存期（OS）。进行Cox回归分析以确定OS的预测因子。
■总的来说，包括74例患者，中位年龄66岁，45.9%的KPS评分≥90分。中位OS为诊断后19.6个月，SABR开始后12.1个月。一年的本地控制率为90％。多变量Cox回归分析确定KPS≥90，年龄<70和SABR之前没有疼痛是OS的独立有利预测因子。≥3级疲劳和晚期胃肠道毒性的发生率为2.7％。
■SABR对化疗后不可切除的LAPC患者是一种耐受性良好的治疗方法。当应用于表现得分较高的患者时，结果会更好，年龄<70岁，没有疼痛。未来的随机试验将必须证实这些发现。
■前瞻性机构数据库收集了接受化疗的LAPC患者的数据，主要是FIRINOX，其次是SABR,使用磁共振引导放射治疗，40Gy在两周内的5个分数。主要终点是总生存期（OS）。进行Cox回归分析以确定OS的预测因子。
■总的来说，包括74例患者，中位年龄66岁，45.9%的KPS评分≥90分。中位OS为诊断后19.6个月，SABR开始后12.1个月。一年的本地控制率为90％。多变量Cox回归分析确定KPS≥90，年龄<70和SABR之前没有疼痛是OS的独立有利预测因子。≥3级疲劳和晚期胃肠道毒性的发生率为2.7％。
■SABR对化疗后不可切除的LAPC患者是一种耐受性良好的治疗方法。当应用于表现得分较高的患者时，结果会更好，年龄<70岁，没有疼痛。未来的随机试验将必须证实这些发现。
